Corbevax, a new patent-free Covid vaccine, is an important step to end pandemic
By H.JanGraFeb 3, 2022
Corbevax was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine.
The CORBEVAX vaccine is a protein subunit vaccine.
It uses a harmless piece of the spike protein from the coronavirus that causes COVID-19 to stimulate and prepare the immune system for future encounters with the virus.
CORBEVAX was developed by the co-directors of the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, Drs. Maria Elena Bottazzi and Peter Hotez.
Protein subunit vaccines have an advantage over mRNA vaccines
They can be readily produced using well-established recombinant DNA technology that is relatively inexpensive and fairly easy to scale up.
The Indian government has ordered 300 million doses of CORBEVAX, and BioE plans to produce more than 1 billion shots for people in developing countries.